Kumar Muthalagappan OBE is a clinical research industry leader with proven expertise in building and scaling global research operations. As CEO and Chairman of MeDiNova, he transformed a small North London clinical research unit into a multinational organization with 106 clinical research sites across eight countries, specializing in trials for asthma, COPD, and osteoporosis while growing turnover from £500,000 to £40 million. He subsequently led Oncacare, a specialized oncology clinical research company. Both organizations were successfully acquired by ICON Plc, the pharmaceutical industry’s largest contract research organization. Kumar currently serves as Strategic Advisor to Vitruvian Partners on healthcare and life sciences matters.
